Literature DB >> 17346476

The effect of second-trimester antibiotic therapy on the rate of preterm birth.

Anne-Maude Morency1, Emmanuel Bujold.   

Abstract

OBJECTIVE: As many as 50% of spontaneous preterm births are infection-related, with Mycoplasma species being the most common microbial isolates from the amniotic cavity. The goal of our study was to evaluate the effect of macrolides, a specific group of antibiotics known to be effective against Mycoplasma species, on the rate of preterm births.
METHODS: We performed a systematic review of the literature and a meta-analysis. We searched PubMed, Medline (1965-March 2006), Embase, and the Cochrane Library, using the key words "pregnancy," "macrolides," "erythromycin," "azithromycin," and "clarithromycin." The research was limited to randomized controlled trials and to human females. Studies included for analysis were of women in the second trimester of pregnancy who received either macrolides or placebo (or no treatment) in order to prevent preterm delivery with at least 95% of patient follow-up. We excluded studies involving women with preterm premature rupture of membranes or regular uterine contractions. Meta-analysis of the retrieved data was performed using RevMan 4.2.8 (Cochrane Collaboration) with dichotomous analyses and delivery prior to 37 weeks' gestation as the primary outcome. The analysis was subsequently repeated using the same methodology for clindamycin and metronidazole administered during the second trimester.
RESULTS: Of the 61 articles yielded by our search, three original papers, investigating a total of 1807 women, examined macrolide utilization and met our criteria. Women included in our analysis were all considered to be at higher risk for preterm delivery (vaginal fetal fibronectin positivity, urogenital Mycoplasma infection, prior preterm delivery, and/or pregestational maternal weight < 50 kg). Compared with placebo, macrolides were associated with a lower rate of preterm births (odds ratio [OR] 0.72; 95% confidence intervals [CI] 0.56-0.93), as was clindamycin (OR 0.68; 95% CI 0.49-0.95). On the other hand, metronidazole (OR 1.10; 95% CI 0.95-1.29) was not linked with significant changes in the rate of preterm births. A higher rate of preterm delivery was found when mid-trimester metronidazole was the only antibiotic administered (OR 1.31; 95% CI 1.08-1.58).
CONCLUSION: Macrolides and clindamycin, given during the second trimester of pregnancy, are associated with a lower rate of preterm delivery, whereas second-trimester metronidazole used alone is linked with a greater risk of preterm delivery in a high-risk population. Use of metronidazole, a common treatment for bacterial vaginosis and Trichomonas vaginalis, should be avoided during the second trimester of pregnancy in this population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346476     DOI: 10.1016/s1701-2163(16)32350-7

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  22 in total

Review 1.  Oral health and adverse pregnancy outcomes - what's next?

Authors:  Y W Han
Journal:  J Dent Res       Date:  2010-11-01       Impact factor: 6.116

Review 2.  Recurrent preterm birth.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Beth L Pineles; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Jimmy Espinoza; Sonia S Hassan
Journal:  Semin Perinatol       Date:  2007-06       Impact factor: 3.300

Review 3.  The Human Ureaplasma Species as Causative Agents of Chorioamnionitis.

Authors:  Emma L Sweeney; Samantha J Dando; Suhas G Kallapur; Christine L Knox
Journal:  Clin Microbiol Rev       Date:  2016-12-14       Impact factor: 26.132

Review 4.  Antenatal prevention of cerebral palsy and childhood disability: is the impossible possible?

Authors:  Stacey J Ellery; Meredith Kelleher; Peta Grigsby; Irina Burd; Jan B Derks; Jon Hirst; Suzanne L Miller; Larry S Sherman; Mary Tolcos; David W Walker
Journal:  J Physiol       Date:  2018-07-21       Impact factor: 5.182

5.  Vaginal and oral microbes, host genotype and preterm birth.

Authors:  Usha Srinivasan; Dawn Misra; Mary L Marazita; Betsy Foxman
Journal:  Med Hypotheses       Date:  2009-12       Impact factor: 1.538

6.  Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model.

Authors:  Peta L Grigsby; Miles J Novy; Drew W Sadowsky; Terry K Morgan; Mary Long; Ed Acosta; Lynn B Duffy; Ken B Waites
Journal:  Am J Obstet Gynecol       Date:  2012-10-23       Impact factor: 8.661

7.  Selected vaginal bacteria and risk of preterm birth: an ecological perspective.

Authors:  Ai Wen; Usha Srinivasan; Deborah Goldberg; John Owen; Carl F Marrs; Dawn Misra; Deborah A Wing; Sreelatha Ponnaluri; Arianna Miles-Jay; Brigette Bucholz; Khadija Abbas; Betsy Foxman
Journal:  J Infect Dis       Date:  2013-11-22       Impact factor: 5.226

Review 8.  Progesterone interactions with the cervix: translational implications for term and preterm birth.

Authors:  Bryan Larsen; Joseph Hwang
Journal:  Infect Dis Obstet Gynecol       Date:  2011-10-27

9.  Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model.

Authors:  Jeffrey A Keelan; Matthew W Kemp; Matthew S Payne; David Johnson; Sarah J Stock; Masatoshi Saito; Prabhavathi Fernandes; John P Newnham
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

Review 10.  Investigating the efficacy and safety of metronidazole during pregnancy; A systematic review and meta-analysis.

Authors:  Priscilla Ajiji; Anil Uzunali; Emmanuelle Ripoche; Emilie Vittaz; Thierry Vial; Patrick Maison
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.